EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Guido Gini iD, Monica Tani iD, Alessandra Tucci iD, Luigi Marcheselli, Marina Cesaretti, Monica Bellei iD, Anna Pascarella iD, Filippo Ballerini iD, Mauro Petrini, Francesco Merli iD, Attilio Olivieri, Francesco Lanza iD und 14 weitere

Blood · 26.10.2023 · 142 (17) · 1438-1447

DOI: 10.1182/blood.2022019173 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Blood, erschienen am 26.10.2023. Verfasst von Guido Gini und 25 weiteren Autor:innen. Beteiligte Einrichtung: Struttura Organizzativa Dipartimentale di Clinica Ematologica, Azienda Ospedaliero Universitaria delle Marche, Università Politecnica delle Marche, A…. Hauptthemen laut MEDLINE: Frail Elderly, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment of diffuse large B-cell lymphoma (DLBCL) in older patients is challenging, especially for those who are not eligible for anthracycline-containing regimens. Fondazione Italiana Linfomi (FIL) started the FIL_ReRi study, a 2-stage single-arm trial to investigate the activity and safety of the chemo-free combination of rituximab and lenalidomide (R2) in ≥70-year-old untreated frail patients with DLBCL. Frailty was prospectively defined using a simplified geriatric assessment tool. Patients were administered a maximum of 6 28-day cycles of 20 mg oral lenalidomide from days 2 to 22 and IV rituximab 375 mg/m2 on day 1, with response assessment after cycles 4 and 6. Patients with partial response or complete response (CR) at cycle 6 were administered lenalidomide 10 mg/d from days 1 to 21 for every 28 cycles for a total of 12 cycles or until progression or unacceptable toxicity. The primary end point was the overall response rate (ORR) after cycle 6; the coprimary end point was the rate of grade 3 or 4 extrahematological toxicity. The ORR was 50.8%, with 27.7% CR. After a median follow-up of 24 months, the median progression-free survival was 14 months, and the 2-year duration of response was 64%. Thirty-four patients experienced extrahematological toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events grade ≥3. The activity of the R2 combination was observed in a significant proportion of subjects, warranting further exploration of a chemo-free approach in frail older patients with DLBCL. This trial was registered at EudraCT as #2015-003371-29 and clinicaltrials.gov as #NCT02955823.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Frail ElderlyLymphoma, Large B-Cell, DiffuseHumansAgedRituximabLenalidomideAntineoplastic Combined Chemotherapy ProtocolsTreatment Outcome

Substanzen

RituximabLenalidomide

Autor:innen und Institutionen

  • Struttura Organizzativa Dipartimentale di Clinica Ematologica, Azienda Ospedaliero Universitaria delle Marche, Università Politecnica delle Marche, Ancona, Italy.
  • Unità di Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy.
  • Unità di Ematologia, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy.
  • Uffici Studi Fondazione Italiana Linfomi, sede di Modena, Modena, Italy.
  • Unità Operativa Complessa di Ematologia, Ospedale dell'Angelo, Venice-Mestre, Italy.
  • Clinica Ematologica, IRCCS Ospedale Policlinico San Martino, Università di Genova, Genoa, Italy.

ORCID-Profile: Guido Gini, Monica Tani, Alessandra Tucci, Monica Bellei, Anna Pascarella, Filippo Ballerini, Francesco Merli, Francesco Lanza, Ombretta Annibali, Vittorio Ruggero Zilioli, Anna Marina Liberati, Maria Chiara Tisi, Annalisa Arcari, Dario Marino, Gerardo Musuraca, Vincenzo Pavone, Alberto Fabbri, Samantha Pozzi, Donato Mannina, Stefano Luminari

Zitieren

APA

Gini, G., Tani, M., Tucci, A., Marcheselli, L., Cesaretti, M., Bellei, M., Pascarella, A., Ballerini, F., Petrini, M., Merli, F., Olivieri, A., Lanza, F., Annibali, O., Zilioli, V. R., Liberati, A. M., Tisi, M. C., Arcari, A., Marino, D., Musuraca, G., …, & Luminari, S. (2023). Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study. Blood, 142(17), 1438-1447. https://doi.org/10.1182/blood.2022019173

Vancouver

Gini G, Tani M, Tucci A, Marcheselli L, Cesaretti M, Bellei M, et al. Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study. Blood. 2023;142(17):1438-1447. doi:10.1182/blood.2022019173

BibTeX
@article{Gini2023,
  author = {Gini, Guido and Tani, Monica and Tucci, Alessandra and Marcheselli, Luigi and Cesaretti, Marina and Bellei, Monica and Pascarella, Anna and Ballerini, Filippo and Petrini, Mauro and Merli, Francesco and Olivieri, Attilio and Lanza, Francesco and Annibali, Ombretta and Zilioli, Vittorio Ruggero and Liberati, Anna Marina and Tisi, Maria Chiara and Arcari, Annalisa and Marino, Dario and Musuraca, Gerardo and Pavone, Vincenzo and Fabbri, Alberto and Pozzi, Samantha and Mannina, Donato and Plenteda, Caterina and Celli, Melania and Luminari, Stefano},
  title = {Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study},
  journal = {Blood},
  year = {2023},
  volume = {142},
  number = {17},
  pages = {1438--1447},
  doi = {10.1182/blood.2022019173}
}
Kostenlos starten →